GSK to buy food allergy drug maker RAPT in $2.2bn deal
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adultsBusiness live – latest updatesGSK, the UK’s second-biggest drugmaker, has unveiled a $2.2bn (£1.6bn) deal to acquire a Californian biotech company which owns a drug that aims to...
<p>US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults</p><ul><li><p><a href="https://www.theguardian.com/business/live/2026/jan/20/davos-von-der-leyen-he-macron-carney-wef-greenland-trump-uk-unemployment-business-live-news-updates">Business live – latest updates</a></p></li></ul><p>GSK, the UK’s second-biggest drugmaker, has unveiled a $2.2bn (£1.6bn) deal to acquire a Californian biotech company which owns a drug that aims to protect against severe food allergies such as nuts, milk and eggs.</p><p>It is the first large deal announced by <a href="https://www.theguardian.com/business/2025/sep/29/gsk-emma-walmsley-to-be-replaced-as-ceo">GSK’s new chief executive Luke Miels</a>, who joined the London-based company in 2017 as chief commercial officer and <a href="https://www.theguardian.com/business/2025/sep/29/emma-walmsley-steadied-gsk-but-doubts-linger-over-growth-targets">took the reins from Emma Walmsley</a> at the start of the year.</p> <a href="https://www.theguardian.com/business/2026/jan/20/gsk-buy-food-allergy-drug-maker-rapt-us-biotech">Continue reading...</a>
Read the full article at:
The Guardian World →